The Relationship between Economic Value Added and Enterprise Value in Taiwan Biotech Industry: The Role of Corporate Characteristic

碩士 === 中國文化大學 === 會計學系 === 103 === In 2002 the United States occurred Enron and Merck accounting scandal, Making the performance evaluation and value measure of traditional accounting has been a se-rious challenge. Therefore, scholars have proposed Economic Value Added (EVA) is one of the best ind...

Full description

Bibliographic Details
Main Authors: SU, CHUAN-CHIH, 蘇傳智
Other Authors: Wang, Mao-Chang
Format: Others
Language:zh-TW
Published: 2015
Online Access:http://ndltd.ncl.edu.tw/handle/y83hac
Description
Summary:碩士 === 中國文化大學 === 會計學系 === 103 === In 2002 the United States occurred Enron and Merck accounting scandal, Making the performance evaluation and value measure of traditional accounting has been a se-rious challenge. Therefore, scholars have proposed Economic Value Added (EVA) is one of the best indicators of performance evaluation. Taiwan's biotechnology industry is one of the star industry. Making the performance evaluation and value measure of the biotechnology industry is a major concern. Based on past literature that EVA is more than the traditional performance measures applicable to the biotechnology industry in Taiwan, And the Corporate Governance and enterprise value with a high correlation. In this paper, 2008-2014 Taiwan Biotech publicly traded companies for the study, Using regression analysis to explore the relevance of EVA and enterprise value, And discuss after joining the company governance variables will affect its relevance. Com-prehensive study found that when the corporate decision-making will help to enhance the EVA, it is able to effectively enhance corporate value. When the company the pro-portion of outside directors accounted for the board seats to reduce and increasing the proportion of institutional investors holding. More to improve the EVA and the enter-prise value helpful. However, the biotechnology industry as a guide of innovative re-search and development of new industries. But in this study, the number of approved patents and research and development intensity to study EVA and the enterprise value of the results are inconsistent. Therefore not be able to increase research and develop-ment investment to enhance the EVA and the enterprise value of the company.